|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Protective Effect of Buyang Huanwu Decoction on Neurovascular Unit in Alzheimer's Disease Cell Model via Inflammation and RAGE/LRP1 Pathway.
|
31625533 |
2019 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these in vitro findings, we found disrupted microvessels near Aβ plaque-deposited areas, elevated RAGE expression, and enhanced MMP secretion in microvessels of the brains of 5XFAD mice, an animal model for AD.
|
22745485 |
2012 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end products (RAGE) binds Abeta and was suggested to be involved in the pathological processes of AD.
|
20145420 |
2009 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Soluble receptor for advanced glycation end products RAGE (sRAGE), a secretory form of RAGE, plays an important role in suppressing RAGE signals that induce pro-inflammatory gene activation in a range of inflammatory diseases, such as Alzheimer's disease, complications of diabetes mellitus and atherosclerosis.
|
23708564 |
2013 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Influence of ADAM10 Polymorphisms on Plasma Level of Soluble Receptor for Advanced Glycation End Products and The Association With Alzheimer's Disease Risk.
|
30555509 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The increased presence of RAGE in the 3xTg-AD animal model showing critical aspects of AD neuropathology indicates that RAGE may contribute to cellular dysfunction in the AD brain.
|
24503708 |
2014 |
|
Alzheimer's Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The present study provides preliminary evidence that the RAGE G82S variant is involved in genetic susceptibility to AD.
|
19902324 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggest that alterations in the LRP-1 and RAGE mediated transport of Abeta take place in AD brains in lesion prone regions and may therefore contribute to SP lesion pathogenesis.
|
18855584 |
2008 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In the present study, the role of RAGE in Abeta production was examined in the brain tissue of an AD animal model, Tg2576 mice, as well as cultured cells.
|
19332646 |
2009 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Careful studies are needed in rodent and nonrodent animal models of AD with new the generation of RAGE antagonists to ensure safety and efficacy in chronic treatment before clinical trials.
|
22571615 |
2012 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Although there is evidence for metabolic dysfunction and chronic inflammation in Alzheimer's disease (AD), circulating levels of soluble receptor for advanced glycation end products (sRAGE) and the receptor for advanced glycation end products (RAGE) ligand S100B have not been characterized. sRAGE is an important mediator in disease as it can act as a ligand decoy for RAGE and attenuate downstream inflammatory signaling.
|
29681765 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
We conclude that blockade of microglial RAGE may have a beneficial effect on Abeta-mediated neuronal perturbation relevant to AD pathogenesis.-Fang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., Chen, J. X., Yan, S. S. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.
|
19906677 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The inhibition of Aβ and its interaction with RAGE may be valuable in proposing the next round of lead compounds for effective Alzheimer's disease treatment.
|
31491967 |
2019 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Altogether, despite a large set of data suggesting that RAGE may represent an interesting target for the pharmacological treatment of AD, the complex functional roles of the receptor would require the use of molecules able to counteract RAGE negative effects without altering the positive ones such as the promotion of adult neurogenesis.
|
27488419 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
sRAGE prolonged stem cell survival and suppressed RAGE-related inflammatory cell and T lymphocyte accumulations in an Alzheimer's disease model.
|
29127006 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature.
|
10082470 |
1999 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Plasma levels of soluble receptor for advanced glycation end products in Alzheimer's disease.
|
27323891 |
2017 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The results provide a molecular basis for altered splicing of mRAGE and esRAGE in AD pathogenesis.
|
25689357 |
2015 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
To address this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat Alzheimer's disease.
|
31028960 |
2019 |
|
Alzheimer's Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Ligand-induced up-regulation of RAGE is involved in various pathophysiological processes, including late diabetic complications and Alzheimer disease.
|
18952609 |
2008 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our findings localize DIAPH1 particularly to myeloid cells in the CNS, especially in AD in the locations of lipid droplet accumulation, thereby implicating RAGE-DIAPH1 signaling in dysregulated lipid metabolism and morphological changes of inflamed myeloid cells in this disorder.
|
29966194 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
The data speak for a weak, but significant effect of AGER on risk of AD.
|
20567859 |
2010 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our data suggest that FPS-ZM1 is a potent multimodal RAGE blocker that effectively controls progression of Aβ-mediated brain disorder and that it may have the potential to be a disease-modifying agent for AD.
|
22406537 |
2012 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
RAGE mediates Aβ accumulation in a mouse model of Alzheimer's disease via modulation of β- and γ-secretase activity.
|
29329433 |
2018 |
|
Alzheimer's Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Alterations in the expression and distribution of the BBB Abeta transporters receptor for advanced glycation end-products and low-density lipoprotein receptor-related protein 1 in AD and the potential roles of apoE4 expression in adversely influencing Abeta burden and BBB permeability are also examined.
|
18379441 |
2008 |